Analystreport

CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Needham & Company LLC from $81.00 to $80.00. They now have a "buy" rating on the stock.

CRISPR Therapeutics AG - Common Shares  (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time